Form 4: Relmada Therapeutics Director Paul Kelly Increases Stake with $25,000 Stock Purchase

Director Paul Kelly of Relmada Therapeutics increased his holdings by purchasing 25,000 shares of common stock at an average price of $2.59 on September 9, 2024.

Summary

• On September 9, 2024, Paul Kelly, a director of Relmada Therapeutics, purchased 25,000 shares of the company's common stock.
• The purchase was made in the open market with prices ranging from $2.50 to $2.64 per share, resulting in a weighted average price of $2.59.
• Following the transaction, Kelly directly owns 212,295 shares of Relmada Therapeutics.
• This transaction was reported on September 11, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director buying shares suggests confidence, but it's a relatively small transaction.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often monitored by investors as an indicator of management's confidence in the company's prospects. It can be a positive signal, especially when a director increases their stake in the company.

Stakeholder Impact

• The stock purchase could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Relmada Therapeutics, RLMD, Paul Kelly, Director, Stock Purchase, Form 4, Beneficial Ownership, Insider Trading